

CONCLUSIONS

CONCLUSIONS

- Trans-catheter intra-arterial therapies and local thermal ablation have proved valuable in the battle against primary and secondary hepatic malignancies.
- Although unresectable primary and secondary hepatic malignancies are associated with high morbidity and mortality, loco-regional therapies hold much promise.
- The unique aspects of all such therapies are their minimal toxicity profiles and highly effective tumor responses while normal hepatic parenchyma is preserved.
- The results of our study show that loco-regional techniques were safe and effective in the treatment of metastatic cancer as demonstrated by a minimal complication rate, acceptable tumor response, and sustained reduction of tumor markers levels
- When using transarterially delivered therapies or loco-regional ablation techniques, meticulous patient selection and careful planning and execution are imperative and should be carried out with the participation of interventional and diagnostic radiologists, and medical and surgical oncologists.
- Despite these major advances in catheter techniques, imaging, and administration, further investigation remains warranted.
- Further investigations of survival statistics with these therapies and of the clinical applicability of gene therapy are still needed.

RECOMMENDATIONS

RECOMMENDATIONS

Loco-regional interventional techniques should be considered one of the most effective and reliable treatment options for unresectable chemo refractory LM. Every physician should keep in mind that **Loco-regional interventional techniques** provide an adequate solution for the more advanced LM.

Co-operation between physicians from different departments (**hepatologists, surgeons, oncologists and interventional radiologists**) is mandatory to determine and provide the most beneficial therapeutic options for these critical patients.

If there are **lesions in both lobes**, the lobe with the largest tumor load is embolized first. TACE should be restricted to a single lobe or major branch of the hepatic artery at one time. The patient may be brought back after 1 month, to complete the procedure in the opposite lobe.

Three-dimensional **volumetric assessment** of the tumor may be performed in preference to the uni-dimensional or bi-dimensional evaluation. As it allows better understanding of the fluctuations in actual tumor size.

Future imaging evaluation of tumor response should routinely incorporate both anatomic and functional information of the tumor burden (PET/CT ,DWI.,SPECT).

REFERENCES

REFERENCES

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. *CA Cancer J Clin* 2005; 55:10-30.
2. Sasson AR, Sigurdson ER. Surgical treatment of liver metastases. *Semin Oncol* 2002; 29:107-18.
3. Curley SA, Izzo F, Delrio P, et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. *Ann Surg* 1999; 230: 1-8.
4. Morris DL, Ross WB, Iqbal J, et al. Cryoablation of hepatic malignancy: an evaluation of tumor marker data and survival in 110 patients. *Gastrointest Cancer* 1996; 1: 247-51.
5. Breedis C, Young C. The blood supply of neoplasms in the liver. *J Pathol* 1954; 30: 969-77.
6. Salem R, Thurston KG. Radioembolization with 90 yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. II. Special topics. *J Vasc Interv Radiol* 2006; 17: 1425-39.
7. Williams P, Warwick R, Dyson M, Bannister L. Anatomy of the alimentary tract. In: *Gray's Anatomy*. 37th ed. Edinburgh: Educational Low-Priced Books Scheme with Churchill Livingstone, 1989. 1384-93.
8. Snell RS. The abdominal cavity. In: *Clinical Anatomy for Medical Students*. 3rd ed. Boston: Little, brown and company, 1986. 203-97.
9. Lomas DJ. The liver. In: Grainger R, Allison D (eds). *Grainger and Allison's Diagnostic Radiology, A Textbook of Medical Imaging*. 4th ed. London: Churchill Livingstone Inc, 2001: 1237-76.
10. Stanley R, Heiken J. Liver. In: Lee J, Saget S (eds). *Computed body tomography with MRI correlation [CD-ROM]*. 3rd ed. New York: Lippincott, Williams and Wilkins, 1998.
11. Fasel J, Gailloud P, Terrier F, et al. Segmental anatomy of the liver: a review and a proposal for an international nomenclature. *European radiology* 1996; 6: 834-7.
12. Agur AM. *Grants Atlas of Anatomy*. 9th ed. Baltimore: Williams and Wilkins, 1991. 102-15.
13. Kadir S. *Atlas of Normal and Variant Angiographic Anatomy*. Philadelphia: W. B Saunders Company, 1991: 97-122.
14. Dick R, Watkinson A. The liver and spleen. In: Sutton D (ed). *Textbook of Radiology and Imaging*. 7th ed. Vol 1. London: Churchill Livingstone, 2003. 737-86.
15. Lee S, Kim T, Byun J, Ha H, et al. Hepatic arteries in potential donors for living related liver transplantation: Evaluation with multi-detector row ct angiography. *Radiology* 2003; 227: 391-9.
16. Lee KH, Sung KB, Lee DY, et al. Trans-catheter Arterial Chemoembolization for Hepatocellular Carcinoma: Anatomic and Hemodynamic Considerations in the Hepatic Artery and Portal Vein. *Radiographics* 2002; 22: 1077-91.

17. Covey A, Brody L, Maluccio M, et al. Variant hepatic arterial anatomy revisited: Digital subtraction angiography performed in 600 patients. *Radiology* 2002; 224: 542-7.
18. Murcia M, Olcott E, Jeffrey R, et al. Focal Liver Lesions: Pattern-based Classification Scheme for Enhancement at Arterial Phase CT. *Radiology* 2000; 215: 746-51.
19. Hassan M, Zaghoul A, El-Serag H, et al. The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients. *J Clin Gastroenterol* 2001; 33: 123-6.
20. Tanaka K, Ikematsu H, Hirohata T, et al. Hepatitis C virus infection and risk of hepatocellular carcinoma among Japanese: possible role of type 1b (II) infection. *J Natl Cancer Inst* 1996; 88: 742-6.
21. Schima W, Kulinna C, Langenberger H, et al. Liver metastases of colorectal cancer: US, CT or MR? *Cancer Imaging* 2005; 5: 149-56.
22. Simmonds PC, Primrose JN, Colquitt JL, et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. *Br J Cancer* 2006; 94: 982-99.
23. Lodge JP. Modern surgery for liver metastases. *Cancer Imaging* 2000; 1: 77-85.
24. Ling-Hui Xu, San-Jun Cai, Guo-Xiang Cai, et al. Imaging diagnosis of colorectal liver metastases. *World J Gastroenterol*. 2011; 17: 4654-9.
25. Bernatik T, Strobel D, Hahn EG, et al. Detection of liver metastases: comparison of contrast-enhanced wide-band harmonic imaging with conventional ultrasonography. *J Ultrasound Med* 2001; 20: 509-15.
26. Schirin-Sokhan R, Winograd R, Roderburg C, et al. Response evaluation of chemotherapy in metastatic colorectal cancer by contrast enhanced ultrasound. *World J Gastroenterol* 2012; 18: 541-5.
27. Kamel IR, Georgiades C, Fishman EK. Incremental value of advanced image processing of multislice computed tomography data in the evaluation of hypervascular liver lesions. *J Comput Assist Tomogr* 2003; 27: 652-6.
28. Sahani D, Mehta A, Blake M, et al. Preoperative hepatic vascular evaluation with CT and MR angiography: implications for surgery. *Radiographics* 2004; 24: 1367-80.
29. Yim PJ, Vora AV, Raghavan D, et al. Volumetric analysis of liver metastases in computed tomography with the fuzzy C-means algorithm. *J Comput Assist Tomogr* 2006; 30: 212-20.
30. Hale HL, Husband JE, Gossios K, et al. CT of calcified liver metastases in colorectal carcinoma. *Clin Radiol* 1998; 53: 735-41.
31. Miles KA, Hayball MP, Dixon AK. Functional images of hepatic perfusion obtained with dynamic CT. *Radiology* 1993; 188: 405-11.
32. Ch'en IY, Katz DS, Jeffrey RB, et al. Do arterial phase helical CT images improve detection or characterization of colorectal liver metastases? *J Comput Assist Tomogr* 1997; 21: 391-7.

33. Kopp AF, Heuschmid M, Claussen CD. Multidetector helical CT of the liver for tumor detection and characterization. *Eur Radiol* 2002; 12: 745-52.
34. Wicherts DA, de Haas RJ, van Kessel CS, et al. Incremental value of arterial and equilibrium phase compared to hepatic venous phase CT in the preoperative staging of colorectal liver metastases: an evaluation with different reference standards. *Eur J Radiol* 2011; 77: 305-11.
35. Fidler JL, Fletcher JG, Reading CC, et al. Preoperative detection of pancreatic insulinomas on multiphasic helical CT. *AJR Am J Roentgenol* 2003; 181: 775-80.
36. King AD, Ko GT, Yeung VT, et al. Dual phase spiral CT in the detection of small insulinomas of the pancreas. *Br J Radiol* 1998; 71: 20-3.
37. Kopka L, Grabbe E. Biphasic liver diagnosis with multiplanar-detector spiral CT. *Radiologe* 1999; 39: 971-8.
38. Kulinna C, Helmberger T, Kessler M, et al. Improvement in diagnosis of liver metastases with the multi-detector CT. *Radiologe* 2001; 41: 16-23.
39. Scott DJ, Guthrie JA, Arnold P, et al. Dual phase helical CT versus portal venous phase CT for the detection of colorectal liver metastases: correlation with intra-operative sonography, surgical and pathological findings. *Clin Radiol* 2001; 56: 235-42.
40. Suzuki C, Jacobsson H, Hatschek T, et al. Radiologic Measurements of Tumor Response to Treatment: Practical Approaches and Limitations. *Radio Graphics* 2008; 28: 329-44.
41. Ong KO, Leen E. Radiological staging of colorectal liver metastases. *Surg Oncol* 2007; 16: 7-14.
42. Bennett GL, Petersein A, Mayo-Smith WW, et al. Addition of gadolinium chelates to heavily T2-weighted MR imaging: limited role in differentiating hepatic hemangiomas from metastases. *AJR Am J Roentgenol* 2000; 174: 477-85.
43. Marcus CD, Ladam-Marcus V, Cucu C, et al. Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. *Crit Rev Oncol Hematol* 2009; 72: 217-38.
44. Ariff B, Lloyd CR, Khan S, et al. Imaging of liver cancer. *World J Gastroenterol* 2009; 15: 1289-300.
45. Schima W, Függer R, Schober E, et al. Diagnosis and staging of pancreatic cancer: comparison of mangafodipir trisodium-enhanced MR imaging and contrast-enhanced helical hydro-CT. *AJR Am J Roentgenol* 2002; 179: 717-24.
46. Hekimoglu K, Ustundag Y, Dusak A, et al. Small colorectal liver metastases: detection with SPIO-enhanced MRI in comparison with gadobenate dimeglumine-enhanced MRI and CT imaging. *Eur J Radiol* 2011; 77: 468-72.
47. Ward J, Robinson PJ, Guthrie JA, et al. Liver metastases in candidates for hepatic resection: comparison of helical CT and gadolinium- and SPIO-enhanced MR imaging. *Radiology* 2005; 237: 170-80.
48. Kim YK, Lee JM, Kim CS, et al. Detection of liver metastases: gadobenate dimeglumine-enhanced three-dimensional dynamic phases and one-hour delayed

- phase MR imaging versus superparamagnetic iron oxide-enhanced MR imaging. *Eur Radiol* 2005; 15: 220-8.
49. Mainenti PP, Mancini M, Mainolfi C, et al. Detection of colo-rectal liver metastases: prospective comparison of contrast enhanced US, multidetector CT, PET/CT, and 1.5 Tesla MR with extracellular and reticulo-endothelial cell specific contrast agents. *Abdom Imaging* 2010; 35: 511-21.
 50. Bipat S, van Leeuwen MS, Comans EF, et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis-meta-analysis. *Radiology* 2005; 237: 123-31.
 51. Kim YK, Ko SW, Hwang SB, et al. Detection and characterization of liver metastases: 16-slice multi-detector computed tomography versus superparamagnetic iron oxide-enhanced magnetic resonance imaging. *Eur Radiol* 2006; 16: 1337-45.
 52. Rappeport ED, Loft A, Berthelsen AK, et al. Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation. *Acta Radiol* 2007; 48: 369-78.
 53. Zech CJ, Herrmann KA, Reiser MF, et al. MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA. *Magn Reson Med* 2007; 6: 43-52.
 54. Blyth S, Blakeborough A, Peterson M, et al. Sensitivity of magnetic resonance imaging in the detection of colorectal liver metastases. *Ann R Coll Surg Engl* 2008; 90: 25-8.
 55. Purandare NC, Dua SG, Arora A, et al. Colorectal cancer – patterns of locoregional recurrence and distant metastases as demonstrated by FDG PET / CT. *Indian J Radiol Imaging* 2010; 20: 284-8.
 56. Pijla MEJ, Chaouib AS, Wahlc RL, et al. Radiology of colorectal cancer. *Eur J Cancer* 2002; 38: 887-98.
 57. Ward J, Guthrie JA, Wilson D, et al. Colorectal hepatic metastases: detection with SPIO-enhanced breath-hold MR imaging--comparison of optimized sequences. *Radiology* 2003; 228: 709-18.
 58. Conlon R, Jacobs M, Dasgupta D, et al. The value of intraoperative ultrasound during hepatic resection compared with improved preoperative magnetic resonance imaging. *Eur J Ultrasound* 2003; 16: 211-6.
 59. Zacherl J, Scheuba C, Imhof M, et al. Current value of intraoperative sonography during surgery for hepatic neoplasms. *World J Surg* 2002; 26: 550-4.
 60. McLoughlin JM, Jensen EH, Malafa M. Resection of colorectal liver metastases: current perspectives. *Cancer Control* 2006;13: 32-41.
 61. Bipat S, van Leeuwen MS, Ijzermans JN, et al. Evidence-base guideline on management of colorectal liver metastases in the Netherlands. *Neth J M* 2007; 65: 5-14.
 62. Folprecht G, Grothey A, Alberts S, et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. *Ann Oncol* 2005; 16: 1311-9.

63. Liu CL, Lo Cm, Fan St. Surgical Resection of Hepatocellular Carcinoma. *Cancer Control* 1996; 3: 55-68.
64. Choi J. Regional Trans-catheter therapy of hepatic neoplasms. *Cancer Control* 1996; 3: 407-13.
65. Patt C, Thuluvath P. Role of Liver Transplantation in the Management of hepatocellular carcinoma. *JVIR* 2002; 13: 205-10.
66. Vlastos G, Smith DL, Singletary E, et al. Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases. *Ann Surg Oncol* 2004; 11: 869-74.
67. Sakamoto Y, Yamamoto J, Yoshimoto M, et al. Hepatic resection for metastatic breast cancer: prognostic analysis of 34 patients. *World J Surg* 2005; 29: 524-7.
68. Elias D, Lasser PH, Montrucolli D, et al. Hepatectomy for liver metastases from breast cancer. *Eur J Surg Oncol* 1995; 21:510-3.
69. Pocard M, Pouillart P, Asselain B, et al. Hepatic resection in metastatic breast cancer: results and prognostic factors. *Eur J Surg Oncol* 2000; 26: 155-9.
70. DeMatteo RP, Palese C, Jarnagin WR, et al. Anatomic segmental hepatic resection is superior to wedge resection as an oncologic operation for colorectal liver metastases. *J Gastrointest Surg* 2000; 4: 178-84
71. Folprecht G, Gruenberger T, Hartmann JT, et al. Cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: A randomized multicenter study (CELIM study). 2009 ASCO Gastrointestinal Cancers Symposium; San Francisco, CA: 2009.
72. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. *Ann Surg* 2004; 240: 644-57.
73. Adam R, Laurent A, Azoulay D, et al. Two-stage hepatectomy: a planned strategy to treat irresectable liver tumors. *Ann Surg* 2000; 232: 777-85.
74. Kinoshita H, Sakai K, Hirohashi K, et al. Preoperative portal vein embolization for hepatocellular carcinoma. *World J Surg* 1986; 10: 803-8.
75. Makuuchi M, Thai BL, Takayasu K, et al. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. *Surgery* 1990; 107: 521-7.
76. Azoulay D, Castaing D, Smail A, et al. Resection of non-resectable liver metastases from colorectal cancer after percutaneous portal vein embolization. *Ann Surg* 2000; 231: 480-6.
77. Goldberg S. Comparison of Techniques for Image-guided Ablation of Focal Liver Tumors. *Radiology* 2002; 223: 304-7.
78. Rhim H, Dodd GD, Chintapalli KN, et al. Radiofrequency Thermal Ablation of Abdominal Tumors: Lessons Learned from Complications. *Radiographics* 2004; 24: 41-52.
79. Bilchik AJ, Wood TF, Allegra D. Radiofrequency Ablation of Unresectable Hepatic Malignancies: Lessons Learned. *Oncologist* 2001; 6: 24-33.

80. Choi H, Loyer EM, DuBrow RA, et al. Radio-frequency Ablation of Liver Tumors: Assessment of Therapeutic Response and Complications. *Radiographics* 2001; 21: 41-54.
81. Livraghi T, Solbiati L, Meloni MF, et al. Treatment of Focal Liver Tumors with Percutaneous Radio-frequency Ablation: Complications Encountered in a Multi-center Study. *Radiology* 2003; 226: 441-5.
82. Gillams AR. The use of radiofrequency in cancer. *Br J Cancer* 2005; 92: 1925-9.
83. Livraghi T, Solbiati G, Meloni F, et al. Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the “test of time approach”. *Cancer* 2003; 97: 3027-35.
84. Goldberg SN, Grassi CJ, Cardella JF, et al. Society of Interventional Radiology Technology Assessment Committee, International Working Group on Image-Guided Tumor Ablation. Image-guided tumor ablation: standardization of terminology and reporting criteria. *Radiology* 2005; 235: 728-39.
85. Ruers T, van Coevorden F, Pierie J, et al. Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Interim results of a randomised phase II study of the EORTCNCRI CCSG-ALM Intergroup 40004 (CLOCC). 2008 ASCO Gastrointestinal Cancers Symposium, Orlando, FL: 2008.
86. Kornprat P, Jarnagin WR, DeMatteo RP, et al. Role of intraoperative thermoablation combined with resection in the treatment of hepatic metastasis from colorectal cancer. *Arch Surg* 2007; 142: 1087-92.
87. Gunabushanam G, Sharma S, Thulkar S, et al. Radiofrequency ablation of liver metastases from breast cancer: results in 14 patients. *J Vasc Interv Radiol* 2007; 18: 64-72.
88. Livraghi T, Goldberg SN, Solbiati G, et al. Percutaneous radio-frequency ablation of liver metastases from breast cancer: initial experience in 24 patients. *Radiology* 2001; 220: 145-9.
89. Lawes D, Chopada A, Gillams A, et al. Radiofrequency ablation (RFA) as a cytoreductive strategy for hepatic metastasis from breast cancer. *Ann R Coll Surg Engl* 2006; 88: 639-42.
90. Chun YS, Vauthey JN, Ribero D, et al. Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival. *J Gastrointest Surg* 2007; 11: 1498-504.
91. Tsai MS, Su YH, Ho MC, et al. Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis. *Ann Surg Oncol* 2007; 14: 786-94.
92. Abeloff MAJ, Niederhuber J, Kastan M, et al. *Clinical Oncology. Liver metastasis.* 3rd ed. Churchill Livingstone: Elsevier, 2004. 1141-71.
93. Kelly C, Cassidy J. Chemotherapy in metastatic colorectal cancer. *Surg Oncol* 2007; 16: 65-70.

94. Paschos KA, Bird N. Current diagnostic and therapeutic approaches for colorectal cancer liver metastasis. *HIPPOKRATIA* 2008; 12: 132-8.
95. Turrini O, Viret F, Guirimand J, et al. Strategies for the treatment of synchronous liver metastasis. *Eur J Surg Oncol* 2007; 33:735-40.
96. Chung J, Park J. Transcatheter arterial chemoembolization of hepatocellular carcinoma. *Bombay Hosp J* 2002; 44: 650-5.
97. Fan J, Ten GJ, He SC, et al. Arterial chemoembolization for hepatocellular carcinoma. *World J Gastroenterol* 1998; 4: 33-3.
98. Baum S, Cope C. Catheter, methods and injectors for superselective catheterization. In: *Abram's Angiography Vascular and Interventional Radiology [CD-ROM]*. 3rd ed. New York: Lippincott, Williams and Wilkins, 1998.
99. Livraghi T. Guidelines for treatment of liver cancer. *Eur J Ultrasound* 2001; 13:167-76
100. Bartlett DL, Berlin J, Lauwers GY, et al. Chemotherapy and Regional Therapy of Hepatic Colorectal Metastases: Expert Consensus Statement. *Ann Surg Oncol* 2006; 13: 1284-92.
101. Liu LX, Zhang WH, Jiang HC. Current treatment for liver metastases from colorectal cancer. *World J Gastroenterol* 2003; 9: 193-200.
102. Gray B, Van Hazel G, Hope M, et al. Randomized trial of SIR-spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. *Ann Oncol* 2001; 12: 1711-20.
103. Kalva SP, Thabet A, Wicky S. Recent advances in transarterial therapy of primary and secondary liver malignancies. *Radiographics* 2008; 28: 101-17.
104. Vogl T, Trapp M, Schroeder H, et al. Transarterial chemoembolization for hepatocellular carcinoma: volumetric and morphologic ct criteria for assessment of prognosis and therapeutic success-results from a liver transplantation center. *Radiology* 2000; 214: 349-57.
105. Stuart K. Chemoembolization in the management of liver tumors. *The Oncologist* 2003; 8: 425-37.
106. He SC, Ten GJ, Fan J, et al. Chemoembolization for hepatic malignant tumors . *World J Gastroenterol* 1998; 4: 33-5.
107. Salem R, Thurston KG. Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. III. Comprehensive literature review and future direction. *J Vasc Interv Radiol* 2006; 17: 1571-94.
108. Cohen AD, Kemeny NE. An update on hepatic arterial infusion chemotherapy for colorectal cancer. *Oncologist* 2003; 8: 553-66.
109. Lygidakis NJ, Sgourakis G, Dedemadi G, et al. Regional chemoimmunotherapy for nonresectable metastatic liver disease of colorectal origin. A prospective randomized study. *Hepatogastroenterology* 2001; 48: 1085-7.

110. Heinrich S, Petrowsky H, Schwinnen I, et al. Technical complications of continuous intra-arterial chemotherapy with 5-fluorodeoxyuridine and 5-fluorouracil for colorectal liver metastases. *Surgery* 2003; 133: 40-8.
111. Herrmann KA, Waggershauer T, Sittek H, et al. Liver intraarterial chemotherapy: use of the femoral artery for percutaneous implantation of catheter-port systems. *Radiology* 2000; 215: 294-9.
112. Skitzki JJ, Chang AE. Hepatic artery chemotherapy for colorectal liver metastases: technical considerations and review of clinical trials. *Surg Oncol* 2002; 11: 123-35.
113. Dizon DS, Kemeny NE. Intrahepatic arterial infusion of chemotherapy: clinical results. *Semin Oncol* 2002; 29: 126-35.
114. Ramsey DE, Kernagis LY, Soulen MC, et al. Chemoembolization of hepatocellular carcinoma. *J Vasc Interv Radiol* 2002; 13: 211-21.
115. Vogl TJ, Mack MG, Balzer JO, et al. Liver metastases: neoadjuvant downsizing with transarterial chemoembolization before laser-induced thermotherapy. *Radiology* 2003; 229: 457-64.
116. Chen MS, Li JQ, Zhang YQ, et al. High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. *World J Gastroenterol* 2002; 8: 74-8.
117. Huang XQ, Huang ZQ, Duan WD, et al. Severe biliary complications after hepatic artery embolization. *World J Gastroenterol* 2002; 8: 119-23.
118. Popov I, Lavrnjic S, Jelic S, et al. Chemoembolization for liver metastases from colorectal carcinoma: risk or a benefit. *Neoplasma* 2002; 49: 43-8.
119. Park SH, Cho YK, Ahn YS, et al. Local recurrence of hepatocellular carcinoma after segmental transarterial chemoembolization: risk estimates based on multiple prognostic factors. *Korean J Radiol* 2007; 8: 111-9.
120. Ji SK, Cho YK, Ahn YS, et al. Multivariate analysis of the predictors of survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization: focusing on superselective chemoembolization. *Korean J Radiol* 2008; 9: 534-40.
121. Lewis AL, Gonzalez MV, Lloyd AW, et al. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. *J Vasc Interv Radiol* 2006; 17: 335-42.
122. Vogl TJ, Zangos S, Eichler K, et al. Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update. *Eur Radiol* 2007; 17: 1025-34.
123. Hong K, Khwaja A, Liapo E, et al. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. *Clin Cancer Res* 2006; 12: 2563-7.
124. Taylor RR, Tang Y, Gonzalez MV, et al. Irinotecan drug eluting beads for use in chemoembolisation: In vitro and in vivo evaluation of drug release properties. *Eur J Pharma Sci* 2007; 30: 7-14.

125. Martin RC, Howard J, Tomalty D, et al. Toxicity of Irinotecan-Eluting Beads in the Treatment of Hepatic Malignancies: Results of a Multi-Institutional Registry. *Cardiovasc Intervent Radiol* 2010; 33: 960-6.
126. Dawson LA, Normolle D, Balter JM, et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. *Int J Radiat Oncol Biol Phys* 2002; 53: 810-21.
127. Geschwind JF, Salem R, Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. *Gastroenterology* 2004; 127(Suppl 1): 194-205.
128. Murthy R, Nunez R, Szklaruk F, et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. *RadioGraphics* 2005; 25(Suppl 1): 41-55.
129. Cromwell LD, Kerber CW. Modification of cyanoacrylate for therapeutic embolization: preliminary experience. *AJR* 1979; 132: 799-801.
130. Winkelbauer FW, Niederle B, Pietschmann F, et al. Hepatic artery embolotherapy of hepatic metastases from carcinoid tumors: value of using a mixture of cyanoacrylate and ethiodized oil. *AJR* 1995; 165: 323-7.
131. Winkelbauer FW, Niederle B, Graf O, et al. Malignant insulinoma: permanent hepatic artery embolization of liver metastasis-preliminary results. *Cardiovasc Intervent Radiol* 1995; 18: 353-9.
132. Pollak JS, White RI. The use of cyanoacrylate adhesives in peripheral embolization. *J Vasc Interv Radiol* 2001; 12: 907-13
133. Ahlman H, Westberg G, Wängberg B, et al. Treatment of liver metastases of carcinoid tumors. *World J Surg* 1996; 20: 196-202.
134. Avila MA, Berasain C, Sangro B, et al. New therapies for hepatocellular carcinoma. *Oncogene* 2006; 25: 3866-84.
135. Brown DB, Geschwind JFH, Soulen MC, et al. Society of interventional radiology position statement on chemoembolization of hepatic malignancies. *Journal of Vascular and Interventional Radiology* 2006; 17: 217-23.
136. Tadavarthy SM, Knight L, Ovitt TW, et al. Therapeutic transcatheter arterial embolization. *Radiology* 1974; 112: 13-6.
137. Wheeler PG, Melia W, Dubbins P, et al. Non-operative arterial embolisation in primary liver tumors. *BMJ* 1979; 2: 242-4.
138. Reed ML, Vaitkevicius VK, Al-Sarraf M, et al. The practicality of chronic hepatic artery infusion therapy of primary and metastatic hepatic malignancies: ten-year results of 124 patients in a prospective protocol. *Cancer* 1981; 47: 402-9.
139. Patt YZ, Mavligit GM, Chuang VP, et al. Percutaneous hepatic arterial infusion (HAI) of mitomycin C and floxuridine (FUDR): an effective treatment for metastatic colorectal carcinoma in the liver. *Cancer* 1980; 46: 261-5.
140. Patt YZ, Chuang VP, Wallace S, et al. Hepatic arterial chemotherapy and occlusion for palliation of primary hepatocellular and unknown primary neoplasms in the liver. *Cancer* 1983; 51: 1359-63.

141. Hirai K, Kawazoe Y, Yamashita K, et al. Arterial chemotherapy and transcatheter arterial embolization therapy for non-resectable hepatocellular carcinoma. *Cancer Chemother Pharmacol* 1989; 23(Suppl): S37-41.
142. Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. *J Hepatol* 2007; 46: 474-81.
143. Constantin M, Fundueanu G, Bortolotti F, et al. Preparation and characterisation of poly(vinyl alcohol)/cyclodextrin microspheres as matrix for inclusion and separation of drugs . *Int J Pharm* 2004; 285: 87- 96.
144. Salem R, Thurston KG. Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. III. Comprehensive literature review and future direction. *J Vasc Interv Radiol* 2006; 17: 1571-93.
145. Tellez C, Benson AB, Lyster MT, et al. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. *Cancer* 1998; 82: 1250-9.
146. Geschwind J, Hong K, Georgiades C. Utility of transcatheter arterial chemoembolization for liver dominant colorectal metastatic adenocarcinoma in the salvage setting Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, San Francisco, Calif: 2006.
147. Albert M, Kiefer MV, Sun W, et al. Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. *Cancer* 2011; 117: 343-52.
148. Vogl TJ, Gruber T, Balzer JO, et al. Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. *Radiology* 2009; 250: 281-9.
149. Dong XD, Carr BI. Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients. *Med Oncol* 2011; 28(Suppl 1): S286-90.
150. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. *Cardiovasc Intervent Radiol* 2007; 30: 6-25.
151. Roche A, Girish BV, de Baère T, et al. Trans-catheter arterial chemoembolization as first line treatment for hepatic metastases from neuroendocrine tumors. *Eur Radiol* 2003; 13: 136-40.
152. Kress O, Wagner HJ, Wied M, et al. Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors: a retrospective single centre analysis. *Digestion* 2003; 68: 94-101.
153. Dominguez S, Denys A, Madeira I, et al. Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours. *Eur J Gastroenterol Hepatol* 2000; 12: 141-3.

154. Drougas JG, Anthony LB, Blair TK, et al. Hepatic artery chemoembolization for the management of patients with advanced metastatic carcinoid tumors. *Am J Surg* 1998; 175: 408-12.
155. Diamandidou E, Ajani JA, Yang DJ, et al. Two phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors. *AJR* 1998; 170: 334-9.
156. Ho AS, Picus J, Darcy MD, et al. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. *AJR Am J Roentgenol* 2007; 188: 1201-7.
157. Hong K, Khwaja A, Liapi E, et al. New intraarterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. *Clin Cancer Res* 2006; 12: 2563-7.
158. Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. *J Hepatol* 2007; 46: 474-81.
159. Reyes DK, Vossen JA, Kamel IR, et al. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. *Cancer J* 2009; 15: 526-32.
160. Taylor RR, Tang Y, Gonzalez MV, et al. Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties. *Eur J Pharm Sci* 2007; 30: 7-14.
161. Martin RC, Joshi J, Robbins K, et al. Hepatic intra-arterial injection of Drug-Eluting Bead, Irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multiinstitutional study. *Ann Surg Oncol* 2010; 18: 192-8.
162. Gray B, Van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. *Ann Oncol* 2001; 12: 1711-20.
163. Van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. *J Surg Oncol* 2004; 88: 78-85.
164. Kennedy AS, Coldwell D, Nutting C, et al. Resin ⁹⁰Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. *Int J Radiat Oncol Biol Phys* 2006; 65: 412-25.
165. Sato KT, Lewandowski RJ, Mulcahy MF, et al. Unresectable chemorefractory liver metastases: radioembolization with ⁹⁰Y microspheres-safety, efficacy, and survival. *Radiology* 2008; 247: 507-15.
166. Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of ⁹⁰Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. *Hepatology* 2008; 47: 71-81.

167. Loewe C, Schindl M, Cejna M. Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol. *AJR* 2003; 180: 1379-84.
168. Kamat PP, Gupta S, Ensor JE, et al. Hepatic arterial embolization and chemoembolization for treatment of patients with metastatic neuroendocrine tumors. *Cancer* 2005; 104: 1590-602.
169. Moertel CG, Johnson CM, McKusick CA, et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. *Ann Intern Med* 1994; 120: 302-9.
170. Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. *Cancer* 2005; 104: 1590-602.
171. Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). *J Clin Oncol* 2006; 24: 1395-403.
172. Ensminger WD, Gyves JW. Clinical pharmacology of hepatic arterial infusion chemotherapy. *Semin Oncol* 1983; 10: 176-82.
173. Alekshun T, Garrett C. Targeted therapies in the treatment of colorectal cancers. *Cancer Control* 2005; 12: 105-10.
174. Elvin A, Skogseid B, Hellman P. Radiofrequency ablation of neuroendocrine liver metastases. *Abdom Imaging* 2005; 30: 427-34.
175. Gillams A, Cassoni A, Conway G, et al. Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. *Abdom Imaging* 2005; 30: 435-41.
176. Henn AR, Levine EA, McNulty W, et al. Percutaneous radiofrequency ablation of hepatic metastases for symptomatic relief of neuroendocrine syndromes. *Am J Roentgenol* 2003; 181: 1005-10.
177. Brace CL, Laeseke PF, Sampson LA, et al. Microwave ablation with multiple simultaneously powered small-gauge triaxial antennas: results from an in vivo swine liver model. *Radiology* 2007; 244: 151-6.
178. Oshima F, Yamakado K, Nakatsuka A, et al. Simultaneous microwave ablation using multiple antennas in explanted bovine livers: relationship between ablative zone and antenna. *Radiat Med* 2008; 26: 408-14.
179. Brace CL, Laeseke PF, Sampson LA, et al. Microwave ablation with a single small-gauge triaxial antenna: in vivo porcine liver model. *Radiology* 2007; 242: 435-40.
180. Yang D, Converse MC, Mahvi DM, et al. Measurement and analysis of tissue temperature during microwave liver ablation. *IEEE Trans Biomed Eng* 2007; 54: 150-5.
181. Bhardwaj N, Strickland AD, Ahmad F, et al. A comparative histological evaluation of the ablations produced by microwave, cryotherapy and radiofrequency in the liver. *Pathology (Phila)* 2009; 41: 168-17.
182. Awad MM, Devgan L, Kamel IR, et al. Microwave ablation in a hepatic porcine model: correlation of CT and histopathologic findings. *HPB (Oxford)* 2007; 9: 357-62.

183. Yu NC, Raman SS, Kim YJ, et al. Microwave liver ablation: influence of hepatic vein size on heat-sink effect in a porcine model. *J Vasc Interv Radiol* 2008; 19: 1087-92.
184. Lu DS, Raman SS, Limanond P, et al. Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. *J Vasc Interv Radiol* 2003; 14: 1267-74.
185. Wright AS, Lee FT Jr, Mahvi DM. Hepatic microwave ablation with multiple antennae results in synergistically larger zones of coagulation necrosis. *Ann Surg Oncol* 2003; 10: 275-83.
186. Strickland AD, Clegg PJ, Cronin NJ, et al. Experimental study of large-volume microwave ablation in the liver. *Br J Surg* 2002; 89:1003-7.
187. Yu NC, Lu DS, Raman SS, et al. Hepatocellular carcinoma: microwave ablation with multiple straight and loop antenna clusters--pilot comparison with pathologic findings. *Radiology* 2006; 239: 269-75.
188. Ng KK, Poon RT, Lo CM, et al. Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma. *J Gastrointest Surg* 2008; 12: 183-91.
189. Seki T, Wakabayashi M, Nakagawa T, et al. Percutaneous microwave coagulation therapy for solitary metastatic liver tumors from colorectal cancer: a pilot clinical study. *Am J Gastroenterol* 1999; 94: 322-7.
190. Shibata T, Niinobu T, Ogata N, et al. Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma. *Cancer* 2000; 89: 276-84.
191. Ogata Y, Uchida S, Hisaka T, et al. Intraoperative thermal ablation therapy for small colorectal metastases to the liver. *Hepatogastroenterology* 2008; 55: 550-6.
192. Boutros C, Somasundar P, Garrean S, et al. Microwave coagulation therapy for hepatic tumors: Review of the literature and critical analysis. *Surg Oncol* 2009; 19: e22-32.
193. Touzios JG, Kiely JM, Pitt SC, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival. *Ann Surg* 2005; 241: 776-85.
194. Vogl TJ, Naguib NN, Zangos S, et al. Liver metastases of neuroendocrine carcinomas: Interventional treatment via transarterial embolization, chemoembolization and thermal ablation. *Eur J Radiol* 2008; 55: 550-6.
195. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. *Cancer* 1981; 47: 207-14.
196. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst* 2000; 92: 205-16.
197. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. *J Hepatol* 2001; 35: 421-30.

198. Riaz A, Memon K, Miller FH, et al. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. *J Hepatol* 2011; 54: 695-704.
199. Keppke AL, Salem R, Reddy D, et al. Imaging of hepatocellular carcinoma after treatment with Yttrium-90 microspheres. *AJR Am J Roentgenol* 2007; 188: 768-75.
200. Salem R, Thurston KG. Radioembolization with 90 Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. I. Technical and methodologic considerations. *J Vasc Interv Radiol* 2006; 17: 1251-78.
201. Miller FH, Keppke AC, Reddy D, et al. Response of liver metastases after treatment with yttrium-90: role of size, necrosis, and PET. *AJR Am J Roentgenol* 2007; 188: 776-85.
202. Deng J, Miller FH, Rhee TK, et al. Diffusion weighted MR imaging for determination of hepatocellular carcinoma response to Yttrium-90 radioembolization. *J Vasc Interv Radiol* 2006; 17: 1195-200.
203. Kamel IR, Reyes DK, Liapi E, et al. Functional MR imaging assessment of tumor response after Y⁹⁰ microsphere treatment in patients with unresectable hepatocellular carcinoma. *J Vasc Interv Radiol* 2007; 18: 49-56.
204. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* 2009; 45: 228-47.
205. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. *Semin Liver Dis* 2010; 30: 52-60.
206. Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma and liver metastasis. *Hepatology* 2005; 42: 1208-36.
207. Kamel IR, Bluemke DA, Eng J, et al. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. *J Vasc Interv Radiol* 2006; 17: 505-12.
208. Kamel IR, Bluemke DA, Ramsey D, et al. Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. *AJR Am J Roentgenol* 2003; 181: 708-10.
209. Kim S, Mannelli L, Hajdu CH, et al. Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction. *J Magn Reson Imaging* 2010; 31: 348-55.
210. Padhani AR, Liu G, Koh DM, et al. Diffusion weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. *Neoplasia* 2009; 11:102-25.
211. Cui Y, Zhang XP, Sun YS, et al. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. *Radiology* 2008; 248: 894-900.
212. Marugami N, Tanaka T, Kitano S, et al. Early detection of therapeutic response to hepatic arterial infusion chemotherapy of liver metastases from colorectal cancer using diffusion-weighted MR imaging. *Cardiovasc Intervent Radiol* 2009; 32: 638-46.

PROTOCOL

CO-RESEARCHER

باحث مساعد

Amr Youssry Hamoda6th grade Student

Faculty of Medicine

University of Alexandria

Phone: 01221274316

E-mail: amryoussry2002@yahoo.com

عمرو يمصري حموده

طالب بالفرقة السادسة

كلية الطب

جامعة الإسكندرية

SUPERVISORS

المشرفون

Prof. Dr. Sherif Elsayed Mahmoud Hegab
 Professor of Radiodiagnosis & intervention ,
 Faculty of Medicine,
 University of Alexandria.

أ.د/ شريف السيد محمود حجاب
 أستاذ الأشعة التشخيصية و التداخلية
 كلية الطب
 جامعة الإسكندرية

Prof. Dr. Gamal Elhoseiny Ateya Ahmed
 Professor of clinical oncology and nuclear
 medicine,
 Faculty of Medicine,
 University of Alexandria.

أ.د/ جمال الحسيني عطيه احمد
 أستاذ الطب النووي و علاج
 الأورام
 كلية الطب
 جامعة الإسكندرية

Dr. Rafik Mohamed Ramadan
 Lecturer of Radiodiagnosis&intervention
 Faculty of medicine ,
 University of Alexandria.

د/ رفيق محمد رمضان
 مدرس الأشعة التشخيصية و التداخلية
 كلية الطب
 جامعة الإسكندرية

أ.د. شريف السيد محمود حجاب
 أستاذ الأشعة التشخيصية و التداخلية
 كلية الطب
 جامعة الإسكندرية

INTRODUCTION

Malignant liver tumours are considered among the most common and lethal neoplastic diseases in Egypt. Malignant liver tumours are significantly more prevalent among older age groups than younger age groups⁽¹⁾.

Malignant liver tumors may be primary or secondary to other tumors. Primary hepatocellular carcinoma (HCC) is a highly malignant tumor of liver cell origin showing poor prognosis. Liver metastases from colorectal tumors are the most common hepatic metastasis; the majority of cases of such metastases are inoperable and have a similarly poor prognosis.⁽²⁾

Hepatic metastases present one of the most challenging problems in clinical oncology. Among metastatic tumors to the liver, the most common is colorectal cancer. For colorectal cancer, the liver is the most common site of manifestation and liver metastases are the leading cause of death in such patients. Other tumors frequently developing hepatic metastases include lung, breast tumors, neuroendocrine tumors and gastrointestinal stromal tumors.⁽³⁻⁵⁾

Currently, the only curative treatment in patients with liver metastases of colorectal cancer is liver resection^(5,6). In addition to systemic chemotherapy, current loco regional therapies of unresectable liver lesions include hepatic arterial infusion of chemotherapeutic drugs, transarterial Chemoembolization(TACE), radiofrequency ablation (RFA), cryotherapy, laser-induced thermotherapy (LITT), and yttrium-90 radioembolization⁽⁶⁾.

Chemoembolization is defined as a selective administration of chemotherapy usually combined with embolization of the vascular supply to the tumor. This treatment results in selective ischemic and chemotherapeutic effects on liver metastases⁽⁷⁻⁹⁾.

Handwritten signature and scribbles.

Chemoembolization is based on the concept that the blood supply to hepatic tumors originates predominantly from the hepatic artery ^(10,11). Therefore, embolization of the hepatic artery can lead to selective necrosis of the liver tumor while it leaves normal parenchyma virtually unaffected ⁽¹⁰⁾. It has been shown that anoxic damage increases vascular permeability and thereby promotes penetration of chemotherapeutic agents into the tumor ⁽¹²⁾. However, number, location, and size of the tumors, status of tumor capsule, blood supply to the cancer, and the interventional skill of the angiographer might influence the response to chemoembolization treatment ^(10,12).

Patients selection should be based on having liver tumors of a type known to respond to chemoembolization, such as HCC, colorectal metastases, neuroendocrine metastases, and ocular melanoma metastases and metastases from gastrointestinal sarcomas. Other tumor types have been treated with chemoembolization with little evidence of benefit ⁽¹³⁾.

In radiofrequency ablation, imaging techniques such as ultrasound, computed tomography (CT) are used to help guide a needle electrode into a cancerous tumor. High-frequency electrical currents are then passed through the electrode, creating heat that destroys the abnormal cells. ⁽⁹⁾

In (LITT) a reproducible thermal injury to the hepatic tumors can be produced with neodymium yttrium aluminum garnet(Nd YAG) lasers leading to spherical volume of coagulative necrosis ⁽¹⁴⁾

Cryoablation is a method of insitu tumor ablation in which subfreezing temperatures are delivered through penetrating or surface cryoprobes ⁽¹⁴⁾.

Pre intervention imaging must include ultrasonography & CT to to define the position and size of the lesions to be treated , CTA to assess the pathway of the portal vein & the vascularity of the tumor. ^(14,15)

Handwritten signature and scribbles at the bottom of the page.

Follow up with tri-phasic CT scans are obtained routinely after 1 month . CT scans are assessed for Changes in tumor morphology , size, overall liver size, to assess tumor vascularity and development of new lesions or metastases⁽¹⁶⁾ .

Levels of tumor markers are measured routinely before and after intervention. A fall in tumor marker levels indicates a response to the interventional procedures while a subsequent rise in tumor markers levels indicates tumor recurrence, which may lead to the repetition of the interventional procedures ^(15,16) .

الشيخ
مكي
مكي

AIM OF THE WORK

The aim of this work is to evaluate the role of interventional radiology in treatment of patients with hepatic deposits.

Handwritten notes:
→
↓
→

SUBJECTS

This study will be conducted on 40 patients with hepatic deposits based on their own history, clinical picture, the imaging procedures, Laboratory investigations and/or biopsy referred to the radio diagnosis and intervention radiology department in Alexandria University Hospitals.

Handwritten signature and scribbles

METHODS

Each patient will be subjected to the following algorithm:

1. Thorough history taking.
2. Complete physical examination.
3. Pre-intervention evaluation of the patient by:
 - a. Triphasic C.T scan of the liver .
 - b. Evaluation of tumor markers levels
 - c. Liver function tests
 - d. Serum urea & creatinine
 - e. Serum Albumin & prothrombine time & activity
 - f. Complete blood count (CBC)
4. Intervention techniques will include one or more of the following:
 - TACE (trans-arterial chemo embolization)
 - Radio frequency
 - Trans- arterial chemo perfusion
 - Bland embolization
5. Routine follow up of the patient after 1month using
 - a. Tri-phasic C.T scan
 - b. tumor markers levels (only if previously elevated)
6. Further 3months &/or 6 months follow up may be done according to patients condition)The procedure may be repeated in cases of revascularization of the tumor feeding vessels or subsequent elevation of the tumor markers levels by one or more of the previously mentioned techniques .
7. The medical ethics will be respected, the patient will be informed about the procedures, a written consent will be done.

The image shows several handwritten signatures and initials in black ink, located below the text of the seventh item in the list. There are approximately four distinct marks, including what appears to be a signature and some initials.

RESULTS

The data obtained from different diagnostic modalities, clinical examination and post-embolization follow up of patients will be collected, tabulated and statistically analyzed.

4-5/11
11/11/2011

DISCUSSION

The obtained results will be discussed and compared in view of the available literature.

Dr.  

REFERENCES

1. Rahman El-Zayadi A, Abaza H, Shawky S, Mohamed MK, Seim OE, Badran HM. Prevalence and epidemiological features of hepatocellular carcinoma in Egypt-a single center experience. *Hepato Res.* 2001 Feb;19(2):170-179.
2. Badawi AF, Michael MS. Risk factors for hepatocellular carcinoma in Egypt: the role of hepatitis-B viral infection and schistosomiasis. *Anticancer Res.* 1999 Sep-Oct;19(5C):4565-9.
3. Pickren JW, Tsukada Y, Lane WW. Liver metastases: analysis of autopsy data. In: Weiss L, Gilbert HA, eds. *Liver metastases*. Boston, Mass: GK Hall Medical, 1982; 2-18.
4. Vogl TJ, Zangos S, Balzer JO, Thalhammer A, Mack MG. Transarterial chemoembolization of liver metastases: indication, techniques, results [in German]. *Rofo* 2002;174(6):675-83.
5. Yamada R, Nakatsuka H, Nakamura K, et al. Hepatic artery embolization in 120 patients with non-resectable HCC. *Radiology* 1983; 143 : 397-401.
6. Gates J, Hartnell GG, Stuart K E, Clouse ME. Chemoembolization of Hepatic Neoplasms: Safety, Complications, and When to Worry. *Radiographica.* 1999; 19: 399-414
7. Wasser K, Giebel F, Fischbach R, Tesch H, Landwehr P. Transarterial chemoembolization of liver metastases of colorectal carcinoma using degradable starch microspheres (Spherex): personal investigations and review of the literature. *Radiology* 2005;45(7):633-43
8. Yan TD, Padang R, Morris DL. Long-term results and prognostic indicators after cryotherapy and hepatic arterial chemotherapy with or without resection for

308

colorectal liver metastases: long-term survival can be achieved in patients with multiple bilateral liver metastases. *J Am Coll Surg* 2006;202(1):100-11.

9. Kim Y, Rhim H, Lim HK, et al: Coagulation Necrosis Induced by Radiofrequency Ablation in the Liver: Histopathologic and Radiologic Review of Usual to Extremely Rare Changes. *Radiographics* March-April 2011; 31:377-90

10. Brown DB, Geschwind JF, Soulen MC, Millward SF, Sacks D. Society of interventional Radiology position statement on chemoembolization of hepatic malignancies. *J Vasc Interv Radiol* 2006;17(2 pt 1):217-23.

11. Gunabushanam G, Sharma S, Thulkar S, et al. Radiofrequency ablation of liver metastases from breast cancer: results in 14 patients. *J Vasc Interv Radiol* 2007; 18:64-72

12. Gertner CT, Buhr HJ, Isbert C. Nonoperative ablation for liver metastases: possibilities and limitations as a curative treatment. *Chirurg* 2005;76(6):557-570, 556-63.

13. Vogl TJ, Zangos S, Eichler K, Yakoob D, Nabil M. Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion—an update. *Eur Radiol* 2007;17(4):1025-34.

14. Gillams AR. Thermal ablation of liver metastases. *Abdom Imaging* 2001; 6:361-68.

15. Jaeger HJ, Mehring UM, Castaneda F, et al. Sequential transarterial chemoembolization for unresectable advanced hepatocellular carcinoma. *Cardiovasc Intervent Radiol* 1996;19(6):388-96

16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst* 2000;92(3):205-16.

Handwritten signature and scribbles at the bottom of the page.

ARABIC SUMMARY

المخلص العربي

كان الهدف من هذه الرسالة تقييم دور التقنيات التداخلية الموضعية (تقنيات الاجتثاث بالكي الحراري وتقنيات الحقن الكيميائي عبر الشرايين) في علاج الاورام الخبيثة الثانويه في الكبد وتحديد المؤشرات المناسبة، الموانع، والآثار الجانبية وفوائد هذه التقنيات.

وتضمن بروتوكول الحقن الكيميائي لدينا استخدام مزيج من عوامل العلاج الكيميائي (ميتوميسين، أدرياميسين، سيسبلاتين) مختلطة مع الزيت المعالج باليود ثم أعقب ذلك حقن جسيمات الإسفنج جلفوم لتحقيق السد الشرياني والانصمام كاملا.

تم تصميم استخدام جسيمات هيدروجيل البولي فينيل الكحول المحمله بعوامل العلاج الكيميائي (إيرينوتكان) كنوع جديد للطريقة لتحسين دقة تسليم عوامل العلاج الكيميائي و تترسب في الغالب داخل أنسجة الورم. .

الإيتريوم-٩٠ المجهرية تحمل بمثابة نقطة مصادر الإشعاع و عند تسليمها عن طريق الشريان الكبدي، تترسب في الغالب داخل أنسجة الورم.

وكانت المعدات المستخدمة في التردد الحراري النظام الطبي ريتا ، ويتكون الجهاز من مولد كهربائي، القطب إبرة، وسادة الأرض. المعدات اللازمة للاجتثاث بالميكروويف تتكون من مولد الميكروويف وأقطاب الإبرة .

في دراستنا، حدثت مضاعفات قليلة، الأكثر شيوعا كانت متلازمة ما بعد الانصمام

نظرا للوقت القصير نسبيا من دراستنا وعدم التجانس النسبي في مجتمع الدراسة، لا يمكن أن تقدر معدلات البقاء على قيد الحياة.

التقنيات التداخلية الموضعية أثبتت أنها فعالة جدا في التسبب في إزالة التغذية الدموية للورم وانكماشه. في أطروحة لدينا في نهاية فترة المتابعة، أظهرت ٥٩.٥٪ من المرضى استجابة جزئية، أظهر ٨.٥٪ استجابة كاملة، ..، وكان ٣٢٪ من المرضى لم يستجيبوا للعلاج .

وقد أثبتت التقنيات التداخلية الموضعية أن تكون مفيدة جدا في تخفيف أعراض المرضى وتحسين أسلوب حياتهم. اعترف العديد من المرضى بأنهم قاموا حياة طبيعية تماما بعد التقنيات التداخلية الموضعية على الرغم من تدهور الأوضاع قبلها. وكان التحسن الكبير في ظروف المرضى استنتاج شائع جدا في دراستنا.

وكان التقييم باستخدام الأشعة المقطعية ثلاثيه المراحل علي الكبد و دلالات الاورام معايير الذهب لتقييم مرحلة ما قبل و ما بعد التقنيات التداخلية الموضعية وكذلك التخطيط للدورات المقبلة و يعد استخدام الأشعة المقطعية ثلاثيه المراحل علي الكبد على نحو صحيح أمر بالغ الأهمية للتشخيص وتحديد القرار السليم للمرضى.

في هذه الدراسة، تم تقييم الاستجابة باستخدام حجم الورم وفقا للمبادئ التوجيهية لمعايير تقييم الاستجابة في الأورام الصلبة . كما تم استخدام توهج الورم كمؤشر على الاستجابة للعلاج على النحو الموصى به من قبل الجمعية الأوروبية لدراسة أمراض الكبد . ولقد ثبت انخفاض في توهج الورم استجابته للتقنيات التداخلية الموضعية في هذه الدراسة.

من ناحية أخرى.... التغييرات الوظيفية تحدث قبل التغيرات في حجم الورم، ويمكن استخدام التصوير الوظيفي ولا سيما التصوير بالانبعاث البوزيتروني و التصوير بالرنين المغناطيسي الوظيفي خاصة الانتشار المرجح و هذا التصوير لديه القدرة على تحديد الاستجابة المبكره للعلاج .

بناء على نتائج هذه الدراسة نستنتج أن

الملخص العربي

لجنة الإشراف

.....
أ.د. شريف السيد محمود حجاب
أستاذ الأشعة التشخيصية والتداخلية
كلية الطب
جامعة الإسكندرية

.....
أ.د. جمال الحسيني عطيه أحمد
أستاذ الطب النووي وعلاج الأورام
كلية الطب
جامعة الإسكندرية

.....
د. رفيق محمد رمضان
مدرس الأشعة التشخيصية والتداخلية
كلية الطب
جامعة الإسكندرية

تقييم دور الاشعه التداخليه في التعامل مع ثانويات اورام الكبد

رسالة علمية مقدمه من

الطبيب
محسن أحمد عبد المحسن
للحصول على درجة

الدكتوراه

فى

الأشعة التشخيصية والتداخلية

موافقون

لجنه المناقشه و الحكم علي الرساله

ا.د. فؤاد سراج الدين محمد

أستاذ الأشعة التشخيصية والتداخلية
كلية الطب
جامعة الإسكندرية

ا.د. شريف السيد محمود حجاب

أستاذ الأشعة التشخيصية والتداخلية
كلية الطب
جامعة الإسكندرية

ا.د. اسامه لطفي العبد

أستاذ الأشعة التشخيصية والتداخلية
معهد الكبد القومي
جامعة المنوفية

تقييم دور الاشعه التداخليه في التعامل مع ثانويات اورام الكبد

رسالة علمية

مقدمة إلى كلية الطب- جامعة الإسكندرية
إستيفاء للدراسات المقررة للحصول على درجة

الدكتوراه

فى

الأشعة التشخيصية والتداخلية

مقدمة من

محسن أحمد عبد المحسن

بكالوريوس الطب والجراحة - جامعة الإسكندرية، ٢٠٠٢
ماجستير الأشعة التشخيصية والتداخلية - جامعة الإسكندرية، ٢٠٠٧

٢٠١٥